title: Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis.
abstract: The p53 is a tumor suppressor gene which may be involved in the development of thyroid cancer. Studies investigating the association between p53 Arg72Pro polymorphism and thyroid cancer risk reported conflicting results. The aim of the meta-analysis was to derive a more precise assessment of the association between p53 Arg72Pro polymorphism and thyroid cancer risk. A literature search of PubMed and Web of Science from their inception through March 2013 was conducted. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to assess the strength of the association. Eight case-control studies were included with a total of 874 thyroid cancer cases and 1,891 controls. The meta-analysis results showed that the p53 Arg72Pro polymorphism was only associated with thyroid cancer risk under the recessive model (ProPro vs. ArgArg/ArgPro: OR = 1.83, 95% CI 1.05-3.20, P = 0.034). However, there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95% CI 0.87-1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95% CI 0.88-3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95% CI 0.66-1.55, P = 0.968). Subgroup by ethnicity showed that there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk in both Caucasians and Asians. Thus, p53 Arg72Pro polymorphism may be associated with thyroid cancer risk, and ProPro genotype is likely to be a risk factor of thyroid cancer.
authors.affiliation: Department of Endocrinology, Shengjing Hospital of China Medical University, Sanhao Street, Shenyang, 110004, China, wuboendo@126.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Wu
authors.forename: Dan
authors.initials: D
authors.lastname: Guo
authors.forename: Ying
authors.initials: Y
authors.lastname: Guo
mesh_terms: D000483:Alleles; D016022:Case-Control Studies; D003062:Codon; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D017594:Publication Bias; D012306:Risk; D013964:Thyroid Neoplasms / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D003062:Codon; D016159:Tumor Suppressor Protein p53
references.citation: J Endocrinol Invest. 2008 Oct;31(10):893-9
references.pmid: 19092295
references.citation: PLoS One. 2012;7(9):e45820
references.pmid: 23029260
references.citation: Cancer Lett. 2004 Jul 16;210(2):151-7
references.pmid: 15183530
references.citation: Nat Rev Cancer. 2013 Feb;13(2):83-96
references.pmid: 23303139
references.citation: Endocr Relat Cancer. 2006 Dec;13(4):1185-93
references.pmid: 17158763
references.citation: Lancet. 2013 Mar 23;381(9871):1046-57
references.pmid: 23668555
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Clin Endocrinol (Oxf). 2013 Aug;79(2):288-93
references.pmid: 23278115
references.citation: Adv Exp Med Biol. 2013;779:309-26
references.pmid: 23288646
references.citation: Radiat Res. 2013 Apr;179(4):383-92
references.pmid: 23373901
references.citation: Int J Oncol. 2002 Nov;21(5):1151-4
references.pmid: 12370767
references.citation: Genet Mol Res. 2010 Nov 16;9(4):2222-9
references.pmid: 21086258
references.citation: Nat Rev Cancer. 2013 Mar;13(3):184-99
references.pmid: 23429735
references.citation: Nat Rev Genet. 2013 Jan;14(1):62-75
references.pmid: 23247436
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Biomed Biotechnol. 2012;2012:891961
references.pmid: 22919278
references.citation: Clin Cancer Res. 2012 Dec 1;18(23):6407-15
references.pmid: 23065429
references.citation: Endocr Relat Cancer. 2009 Jun;16(2):491-503
references.pmid: 19286843
references.citation: Cell. 2013 Jan 31;152(3):417-29
references.pmid: 23374339
references.citation: Oncol Rep. 2006 Apr;15(4):949-56
references.pmid: 16525684
references.citation: Lancet. 2013 Mar 23;381(9871):1058-69
references.pmid: 23668556